linjc16/ctgov huggingface dataset:
Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma

Study Overview
=================
Brief Summary
-----------------
Aim of the work: Is to evaluate the prognosis of single burr hole under local anesthesia in management of CSDH according to clinical picture, risk factors, and age.

Detailed Description
-----------------
Patients and methods: We studied 67 consecutive patients with CSDH operated by single burr hole craniostomy under local anaesthesia from Mars, 2014 to February, 2015 in Zagazig University Hospitals according to the aetiology, clinical picture, risk factors, and complications.

Official Title
-----------------
Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma

Conditions
-----------------
Chronic Subdural Hematoma

Intervention / Treatment
-----------------
* Procedure: single burr hole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:chronic subdural hematoma above 19 years old - Exclusion Criteria:age below 19 years acute subduralhematoma uncoperative patients -

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: operated group<br>patients undergoing surgery for chronic subdural hematoma by single burr hole under local anaesthesia | Procedure: single burr hole<br>* patients with CSDH operated by single burr hole craniostomy under local anaesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glasgow Outcome Scale | The Glasgow Outcome Scale was used as measuremabilityent for neurological oucome after surgery.The patients were classified as as dead, persistant vegetative state, severe disability, moderate disability, and mild dis | 6 months postoperative |
Epidemiological and Clinical Characteristics of Critically Ill Patients With COVID-19

Study Overview
=================
Brief Summary
-----------------
Objective of this observational multicentric retrospective-prospective study is to describe the number and the characteristics of patients with Reverse Transcription Polymerase Chain Reaction (RT-PCR) for SARS-CoV2 positivity admitted to Intensive Care Units during the first 6 months of epidemic.

Official Title
-----------------
Epidemiological and Clinical Characteristics of Patients With COVID-19 Admitted in Italian Intensive Care Units: a Multicentric Retrospective-prospective Cohort Study.

Conditions
-----------------
COVID-19, Critical Illness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adulthood Informed consent obtained Exclusion Criteria: No informed consent obtained

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall number and characteristics of patients with COVID-19 in ICU | Number and characteristics of patients with COVID-19 admitted in Intensive Care Units every week. | 22nd February - 22nd August 2020 |
Acute Neuroimmune Effects of Alcohol Using Free Water Imaging

Study Overview
=================
Brief Summary
-----------------
This study examines the effects of moderate alcohol intake on the brain, the immune system, and cognition.

Detailed Description
-----------------
The study involves a within-subjects, pre/post design to assess the effects of a moderate dose of alcohol on immune biomarkers, neurobiological measures, and cognitive functioning. The study recruits healthy adults (ages 21-45) from the community to complete the experimental protocol. Participants complete magnetic resonance imaging scans, blood sample collection, and cognitive testing in the context of alcohol consumption.

Official Title
-----------------
Acute Neuroimmune Effects of Alcohol Using Free Water Imaging

Conditions
-----------------
Alcohol Drinking

Intervention / Treatment
-----------------
* Drug: Ethanol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 21-45 years Able to speak and read English at least at 8th grade level Moderate self-reported alcohol use in the past year Body mass index in normal to overweight range Right-handed Exclusion Criteria: History of heavy drinking Currently seeking alcohol or drug treatment Chronic disease requiring use of medication Recent antibiotic or probiotic use Chronic daily use of NSAIDs Chronic GI disorder Use of illicit drugs Major psychiatric disorder or suicidality Fainting, weakness, infection, excessive bruising, or distress resulting from standard blood draw Safety contraindication for MRI scan Inability to abstain from use of tobacco products prior to or during study Inability to abstain from use of cannabis prior to or during study Pregnant, nursing, or may become pregnant

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ethanol|Moderate alcohol consumption|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune biomarkers |  | 1-3 hours after alcohol intake |
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the ability of darbepoetin alfa to maintain hemoglobin concentrations greater than or equal to 10 g/dL when administered every 3 weeks (Q3W).

Official Title
-----------------
A Randomized, Open-Label, Pilot Study to Evaluate Every Three Week Maintenance Dosing of Darbepoetin Alfa Therapy in Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy

Conditions
-----------------
Neoplasms, Anemia

Intervention / Treatment
-----------------
* Drug: darbepoetin alfa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Subjects with non-myeloid malignancies - Anemia (screening hemoglobin concentration greater than or equal to 10.5 g/dL but less than or equal to 12.0 g/dL) related to cancer and chemotherapy - At least 8 additional weeks of cyclic chemotherapy planned regardless of schedule - Karnofsky Performance Status of greater than or equal to 50% - Serum creatinine concentration less than or equal to 2.0 mg/dL Exclusion Criteria: - Iron deficiency - Red blood cell (RBC) transfusion within 4 weeks of screening - Unstable cardiac disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: darbepoetin alfa|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the ability of darbepoetin alfa to maintain hemoglobin concentrations greater than or equal to 10 g/dL when administered every 3 weeks (Q3W) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess safety profile of subjects treated with darbepoetin alfa |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anemia, darbepoetin alfa, Amgen, Non-myeloid Malignancies
Clinical and Molecular Aspects of Early Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
The etiology of osteoarthritis is varied, ranging from multifactorial, environmental to monogenic. In individuals in whom osteoarthritis appears earlier than in the general population, it is called early osteoarthritis. To our knowledge, there are no large-scale genetic studies on people with early osteoarthritis. The investigators therefore sought to study the causes of monogenic osteoarthritis in people suffering from early non-syndromic osteoarthritis. Material and method From 2013 to 2019, experts in constitutional bone disease sent patients with non-syndromic early osteoarthritis for genetic analysis to our center of competence for constitutional bone diseases. The sequencing of a panel of genes was carried out by NGS.

Official Title
-----------------
Clinical and Molecular Aspects of Early Osteoarthritis

Conditions
-----------------
Early Osteoarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients with early osteoarthritis who have undergone genetic sequencing Exclusion Criteria: - Patients refusing to participate in research

Ages Eligible for Study
-----------------
Minimum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| identification of genetic mutation | sequencing out by NGS | 1 day | 
| number of genetic mutation | sequencing out by NGS | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genetic sequencing
The Impact of a Serious Game on Improving Patient's Medication Knowledge

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effects of an interactive educational program delivered through a patient portal on patients' medication knowledge and medication adherence.

Official Title
-----------------
The Impact of a Serious Game on Improving Patient's Medication Knowledge

Conditions
-----------------
Health Knowledge, Attitudes, Practice

Intervention / Treatment
-----------------
* Behavioral: MasterMed
* Behavioral: Usual Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: MGH Internal Medical Associates patients are age of 18 or older, have at least two medications on their medication list that match our pre-selected medications, have at least three medical conditions on their problem list that match our pre-selected medical conditions, have at least three medications documented on their medication list, and list English as their primary language. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MasterMed<br>MasterMed, an online interactive educational program | Behavioral: MasterMed<br>* An online interactive educational program<br>|
| Placebo Comparator: Usual care<br>Access to an online patient portal | Behavioral: Usual Care<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| medication knowledge |  | 3 months | 
| medication adherence |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patient education, primary health care
Popliteal Artery Entrapment Syndrome & TRanscutaneoUS Oxymetry

Study Overview
=================
Brief Summary
-----------------
Aim of the study is to test the feasibility of transcutaneous oxygen pressure (TcPO2) recording in the diagnosis of popliteal entrapment syndrome (PES) in 30 patients with suspected PES and 30 asymptomatic control heathy subjects

Detailed Description
-----------------
Patients suspected of PES and healthy cpontrols after detailled explanation of the protocol will have a recording of tcpO2 on both calves and will perform a series of elevation on foot in the standing position.

Official Title
-----------------
Application de l'oxymétrie Dynamique Pour le Diagnostic Des pièges artériels poplités

Conditions
-----------------
Popliteal Entrapment Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: Transcutaneous oximetry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years Insurance company alffiliation Symptoms consistent with PES (patients) or absence of symptoms (controls) Exclusion Criteria: Refuse to participate Exclusion period from another protocole

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: transcutaneous oximetry
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients<br>Patients suspected of PES will have a transcutaneous oximetry test during tiptoeing | Diagnostic Test: Transcutaneous oximetry<br>* Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves<br>|
| Sham Comparator: Controls<br>Healthy asymptomatic athletes will have a transcutaneous oximetry test during tiptoeing | Diagnostic Test: Transcutaneous oximetry<br>* Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of a significant DROP decrease | Comparison of DROP value between PES patients and controls | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diagnosis, Peripheral artery disease, sports
Ultrasound Device for Hair Removal

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of the Cutera UHAIR ultrasound device for hair removal.

Detailed Description
-----------------
The purpose of this study is to evaluate the Cutera UHAIR device for safety and efficacy for removal and long term reduction of unwanted hair on subjects with Fitzpatrick skin types I-IV and dark (black or brown), red, and blonde colored hair. At investigator's discretion, each subject will receive treatments and will be scheduled for follow-up visits after the final treatment. The treated area(s) will be photographed at each visit for analysis.

Official Title
-----------------
Cutera UHAIR for Hair Removal

Conditions
-----------------
Hair Removal

Intervention / Treatment
-----------------
* Device: Cutera Ultrasound Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female at least 18 years of age Fitxpatrick skin type I-IV Area with unwanted hair Subject must be able to read, understand and sign the consent form Subject must adhere to the follow-up schedule and study instruction Exclusion Criteria: Simultaneous participation in any other clinical study Inability or unwillingness to follow the treatment schedule Inability or unwillingness to sign the informed consent Infection in the target area Any disease or condition that could impair wound healing History of keloid formation History of malignant tumors in the target area Skin abnormalities in the target area, e.g. cuts, scrapes, wounds, scars, large moles History of hair removal in target area (light based or electrolysis) Pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Site treated with UHAIR<br>The arm, calf, and thigh will be treated | Device: Cutera Ultrasound Device<br>* Pulse duration 10-100 ms, fluence greater or equal to 50 J/cm2, contact tip temperature 5-30 celsus, frequency 5-20 MHz.<br>* Other names: UHAIR;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in Hair Count in the Treated Area | Percent hair reduction 3 months post final treatment compared to baseline in the treated areas | baseline and 3 months post final treatment (up to 28 weeks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hair Reduction Arm Leg, Unwanted hair
The Effect of Timing of Removal of Wound Dressing on Surgical Site Infection Rate After Cesarean Delivery

Study Overview
=================
Brief Summary
-----------------
A randomized controlled trial measuring surgical site infection rate as a function of timing of wound dressing removal.

Detailed Description
-----------------
A randomized controlled trial with a sample size of 602 patients to study the effect of timing of wound dressing removal on the surgical site infection rate. 300 patients were randomized to a group that had the wound dressing removed between 12-30 hours postoperatively. 302 patients were randomized to a group that had the wound dressing removal between 30-48 hours postoperatively. Statistical analyses were performed to determine if the timing of dressing removal had statistical significance on the surgical site infection rate, the primary outcome.

Official Title
-----------------
The Effect of Timing of Removal of Wound Dressing on Surgical Site Infection Rate After Cesarean Delivery

Conditions
-----------------
Surgical Site Infection

Intervention / Treatment
-----------------
* Other: Wound dressing removal.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients ages 18-50 years; medically competent (no proxies or prisoners); and multifetal and singleton gestations from 23 0/7 weeks to 42 0/7 weeks gestational age. Exclusion Criteria: Inability to obtain informed consent; fetal death; immunocompromised patients; patients taking immuno-suppressants; history of documented surgical site infection; or patients requiring reoperation within the 6 week postoperative period for indications other than wound dehiscence/debridement/infection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Wound dressing removal was performed between 12-30 hours postoperatively. | Other: Wound dressing removal.<br> <br> |
| Active Comparator: 2<br>Wound dressing removal was performed between 30-48 hours postoperatively. | Other: Wound dressing removal.<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgical Site infection Rate | Cellulitis, purulent drainage, abscess or wound requiring drainage, debridement, and antibiotics associated with a clinical diagnosis of infection. Any disruption of fascia or subcutaneous skin. | 6 weeks postoperatively |
Long Term Effect of an Education and Training Program for Patients With Chronic Obstructive Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
A parallell group study comparing the effect of an education program with an education and training program for patients with COPD. 30 participants in each group. Participants self-select which group they wanted to be in. Main outcome is SGRQ (a HQoL for patients with COPD).

Official Title
-----------------
Long Term Effect of an Education and Training Program for Patients With Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Behavioral: education and training program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with COPD (FEV1<75% of expected) who have the ability to conversation and active participation will be included. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: education and training program|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| St Geoprg Respiratory Questionnaire (SGRQ) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COPD-Efficacy scale (Norwegian short version), Breathing Problems Questionnaire (BPQ), journal examinations, FVC, FEV1, six minutes walking test with registration of shortness of breath and pulseoxymetrical data. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patient education